SuperworthLeonaBio EPS LONA
Diluted earnings per share by quarter and over the last twelve months, from 2019.
- Last 12 months, to Jun 30, 2026
- −$19.75
- Latest quarter, Q2 FY26
- −$0.80
- Fiscal year 2025
- −$21.34
LeonaBio's earnings per share was −$19.75 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.80.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$21.34 | n/a |
| FY2024 | −$25.24 | n/a |
| FY2023 | −$31.00 | n/a |
| FY2022 | −$25.40 | n/a |
| FY2021 | −$14.90 | n/a |
| FY2020 | −$23.20 | n/a |
| FY2019 | n/a | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.80 | n/a | −$19.75 | |
| Q1 FY26 | −$1.73 | n/a | −$20.73 | |
| Q4 FY25 | −$15.54 | n/a | −$21.34 | |
| Q3 FY25 | −$1.68 | n/a | −$9.68 | |
| Q2 FY25 | −$1.78 | n/a | −$15.46 | |
| Q1 FY25 | −$2.34 | n/a | −$20.68 | |
| Q4 FY24 | −$3.88 | n/a | −$25.24 | |
| Q3 FY24 | −$7.46 | n/a | −$28.56 | |
| Q2 FY24 | −$7.00 | n/a | −$29.80 | |
| Q1 FY24 | −$6.90 | n/a | −$30.60 | |
| Q4 FY23 | −$7.20 | n/a | −$31.00 | |
| Q3 FY23 | −$8.70 | n/a | −$31.80 |
Against its peers
Companies in Healthcare nearest LeonaBio's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| LONALeonaBio | −$19.75 | |
| ATNMActinium Pharmaceuticals | $0.36 | |
| NEPHNephros | $0.16 | +33% a year |
| APTAlpha Pro Tech | $0.41 | +24% a year |
| SPROSpero Therapeutics | $0.11 | |
| LFVNLifevantage | $0.40 | −46% a year |
| ICCCImmucell | $0.08 | −58% a year |
| KEQUKewaunee Scientific | $2.76 | −33% a year |
| PDEXPro DEX | $4.11 | +52% a year |
| PLXProtalix BioTherapeutics | $0.23 | +283% a year |
| NATRNatures Sunshine Products | $1.01 | +36% a year |
| Peer median | $0.38 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on LeonaBio
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.